Close this search box.
Trending now:  
Vessel-Level Coronary Atherosclerotic Plaque Activity Predicts Myocardial Infarction Risk
DanGer Shock: Microaxial Flow Pump versus Standard Care in Infarct-Related Cardiogenic Shock
EuroPCR 2024 Highlights
EuroPCR 2024 Top 10 Highlights
TAVI vs. Surgery in Low-Risk Patients with Severe Aortic Stenosis: Insights from the NOTION-2 Trial

Content for healthcare professionals only

News |

RELIEVE-HF: Interatrial shunt in patients with heart failure

25 Apr 2024

RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heart failure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/heart transplantation, HF hospitalizations, worsening HF, and KCCQ score changes. Among patients with HFpEF, those who received the shunt experienced poor outcomes than those who did not. In contrast, outcomes were better in patients with HF with reduced EF (HFrEF). Patients with HFrEF who received the shunt experienced 55% fewer cardiovascular events than those who did not.

Learn more about the highlights from ACC 2024.

For more cardiology research news join our newsletter or follow us on TwitterFacebookLinkedIn or Instagram.

Reference: Stone GW. A double-blind, randomized, placebo-procedure-controlled trial of an interatrial shunt in patients with HFrEF and HFpEF: principal results from the RELIEVE-HF trial. Presented at: ACC 2024. April 6, 2024. Atlanta, GA.


    Related Topics

    Related Articles